5PSQ-068 Prescription profile of lapatinib in her2-positive breast cancer patients
BackgroundLapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival rates.PurposeTo analyse the prescription profile used and the demographic and clinical characteristics of HER2-positive breast cancer (BC) patients...
Saved in:
Published in | European journal of hospital pharmacy. Science and practice Vol. 25; no. Suppl 1; p. A196 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.03.2018
BMJ Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundLapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival rates.PurposeTo analyse the prescription profile used and the demographic and clinical characteristics of HER2-positive breast cancer (BC) patients treated with lapatinib.Material and methodsA retrospective observational study was performed. Patients with HER2-positive BC aged ≥18 years were included and with a minimum follow-up of 5 years after diagnosis.Clinical and socio-demographic data were collected through the digital medical record. The variables were: family background of BC, lymph node involvement, oestrogen and progesterone receptors, ki67 antigen, stage, tumour size, histological type, treatments prescribed and overall survival (OS). OS was measured as the time from the diagnosis of the disease to the date of exitus or end of the follow-up.ResultsWe included 35 patients with a mean age of 46±10.1 years. Twenty patients (20/35) had lymph node involvement. Fifty per cent were pre-menopausal. Six patients (6/34) presented family background of BC. Fourteen patients (14/35) developed brain metastases during their illness. All patients presented ductal infiltrating histological type. Oestrogen and progesterone receptors were positive in 53.3% and 66.6%, respectively. 46.1% of the patients had a high ki67 index. 64.9% of the patients had early stages and only one patient had a stage IV at the moment of the diagnosis. Tumour size was 2.42±0.93 cm. All patients progressed after the initial treatment with combinations of radiotherapy, anthracyclines, taxanes and trastuzumab and hormonal treatment according to their hormone receptor positivity. Lapatinib therapy was initiated along with capecitabine in the third line in four patients, fourth and fifth line in 10 patients, respectively. Four patients started the drug in the sixth line and two in the eighth line as off-label therapy together with pegylated liposomal doxorubicin. Four patients did not die during the follow-up period and the mean OS was 60.2 months.ConclusionLapatinib has been used in all patients in late lines even as an off-label treatment when alternatives were no longer available. Initially the majority of the patients did not present metastases although later they developed it and the OS was around 5 years.No conflict of interest |
---|---|
AbstractList | Background Lapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival rates. Purpose To analyse the prescription profile used and the demographic and clinical characteristics of HER2-positive breast cancer (BC) patients treated with lapatinib. Material and methods A retrospective observational study was performed. Patients with HER2-positive BC aged ≥18 years were included and with a minimum follow-up of 5 years after diagnosis. Clinical and socio-demographic data were collected through the digital medical record. The variables were: family background of BC, lymph node involvement, oestrogen and progesterone receptors, ki67 antigen, stage, tumour size, histological type, treatments prescribed and overall survival (OS). OS was measured as the time from the diagnosis of the disease to the date of exitus or end of the follow-up. Results We included 35 patients with a mean age of 46±10.1 years. Twenty patients (20/35) had lymph node involvement. Fifty per cent were pre-menopausal. Six patients (6/34) presented family background of BC. Fourteen patients (14/35) developed brain metastases during their illness. All patients presented ductal infiltrating histological type. Oestrogen and progesterone receptors were positive in 53.3% and 66.6%, respectively. 46.1% of the patients had a high ki67 index. 64.9% of the patients had early stages and only one patient had a stage IV at the moment of the diagnosis. Tumour size was 2.42±0.93 cm. All patients progressed after the initial treatment with combinations of radiotherapy, anthracyclines, taxanes and trastuzumab and hormonal treatment according to their hormone receptor positivity. Lapatinib therapy was initiated along with capecitabine in the third line in four patients, fourth and fifth line in 10 patients, respectively. Four patients started the drug in the sixth line and two in the eighth line as off-label therapy together with pegylated liposomal doxorubicin. Four patients did not die during the follow-up period and the mean OS was 60.2 months. Conclusion Lapatinib has been used in all patients in late lines even as an off-label treatment when alternatives were no longer available. Initially the majority of the patients did not present metastases although later they developed it and the OS was around 5 years. No conflict of interest BackgroundLapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival rates.PurposeTo analyse the prescription profile used and the demographic and clinical characteristics of HER2-positive breast cancer (BC) patients treated with lapatinib.Material and methodsA retrospective observational study was performed. Patients with HER2-positive BC aged ≥18 years were included and with a minimum follow-up of 5 years after diagnosis.Clinical and socio-demographic data were collected through the digital medical record. The variables were: family background of BC, lymph node involvement, oestrogen and progesterone receptors, ki67 antigen, stage, tumour size, histological type, treatments prescribed and overall survival (OS). OS was measured as the time from the diagnosis of the disease to the date of exitus or end of the follow-up.ResultsWe included 35 patients with a mean age of 46±10.1 years. Twenty patients (20/35) had lymph node involvement. Fifty per cent were pre-menopausal. Six patients (6/34) presented family background of BC. Fourteen patients (14/35) developed brain metastases during their illness. All patients presented ductal infiltrating histological type. Oestrogen and progesterone receptors were positive in 53.3% and 66.6%, respectively. 46.1% of the patients had a high ki67 index. 64.9% of the patients had early stages and only one patient had a stage IV at the moment of the diagnosis. Tumour size was 2.42±0.93 cm. All patients progressed after the initial treatment with combinations of radiotherapy, anthracyclines, taxanes and trastuzumab and hormonal treatment according to their hormone receptor positivity. Lapatinib therapy was initiated along with capecitabine in the third line in four patients, fourth and fifth line in 10 patients, respectively. Four patients started the drug in the sixth line and two in the eighth line as off-label therapy together with pegylated liposomal doxorubicin. Four patients did not die during the follow-up period and the mean OS was 60.2 months.ConclusionLapatinib has been used in all patients in late lines even as an off-label treatment when alternatives were no longer available. Initially the majority of the patients did not present metastases although later they developed it and the OS was around 5 years.No conflict of interest |
Author | Paredes, A Madrid Herrera, S Guijarro Garre, M Cañadas Casanova, N Martínez |
Author_xml | – sequence: 1 givenname: A Madrid surname: Paredes fullname: Paredes, A Madrid organization: Queen’s University, School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK – sequence: 2 givenname: S Guijarro surname: Herrera fullname: Herrera, S Guijarro organization: Queen’s University, School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK – sequence: 3 givenname: N Martínez surname: Casanova fullname: Casanova, N Martínez organization: Queen’s University, School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK – sequence: 4 givenname: M Cañadas surname: Garre fullname: Garre, M Cañadas organization: Queen’s University, School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK |
BookMark | eNp9kctKAzEUhoNUsNa-w6DrqblMJslGkOINClas65BJM07KNImZacGdG1_UJ3GGXsCNq3PgfOc_P-c_BwPnnQHgEsEJQiS_NqsqVCquUwwRT42qgvaunGQYn4AhhhlLhcizwbGn-RkYN40tICWEi4yIIVjQ-etLCnP-8_U9j6bR0YbWepeE6Etbm8SXSa2Caq2zRWJdUpmI0-Ab29qtSYpoVNMmWjltYtJjxrXNBTgtVd2Y8b6OwNv93WL6mM6eH56mt7O0wFDgFOssKxVVomBIMFZyaqBAHGFOuWYMccMEwZqjkpllqQnNlwUmUGSUCJVDTkbgZqcbNsXaLHV3O6pahmjXKn5Kr6z8O3G2ku9-KxklFLNe4GovEP3HxjStXPlNdJ1niWlH5DzH5F8KItj9knDUUXRHFevV0QKCso9KHqLqF7g8RCW7qMgv2DmOYw |
ContentType | Journal Article |
Copyright | 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2018 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2018 |
Copyright_xml | – notice: 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: 2018 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2018 |
DBID | 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. PQEST PQQKQ PQUKI PRINS 5PM |
DOI | 10.1136/ejhpharm-2018-eahpconf.422 |
DatabaseName | ProQuest Central (Corporate) Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland AUTh Library subscriptions: ProQuest Central BMJ Journals ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
DatabaseTitle | ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest One Academic Eastern Edition ProQuest One Academic Eastern Edition |
Database_xml | – sequence: 1 dbid: 7X7 name: Health & Medical Collection (Proquest) url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2047-9964 |
EndPage | A196 |
GroupedDBID | 0R~ 3V. 53G 7X7 8FI 8FJ AAYAA ABKRM ABUWG ABVAJ ABWEH ADBBV ADMRH AFKRA AHMBA AHQMW AJYBZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BENPR BPHCQ BTHHO C45 CCPQU CXRWF EBS EJD FYUFA H13 HAJ HMCUK HYE OK1 OVD PQQKQ PROAC RHI RMJ RPM TEORI UKHRP 7XB 8FK K9. PQEST PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-b2092-2c44fa5a9b71977f85e091812858c7718e7932c81f7edfc356db23094539a6083 |
IEDL.DBID | RPM |
ISSN | 2047-9956 |
IngestDate | Tue Sep 17 21:18:00 EDT 2024 Thu Oct 10 20:36:08 EDT 2024 Thu Oct 10 19:31:25 EDT 2024 Wed Aug 21 03:28:43 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b2092-2c44fa5a9b71977f85e091812858c7718e7932c81f7edfc356db23094539a6083 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535278 |
PQID | 2010338381 |
PQPubID | 2040966 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535278 proquest_journals_2552768623 proquest_journals_2010338381 bmj_primary_10_1136_ejhpharm_2018_eahpconf_422 |
PublicationCentury | 2000 |
PublicationDate | 20180301 |
PublicationDateYYYYMMDD | 2018-03-01 |
PublicationDate_xml | – month: 03 year: 2018 text: 20180301 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
PublicationTitle | European journal of hospital pharmacy. Science and practice |
PublicationYear | 2018 |
Publisher | BMJ Publishing Group LTD BMJ Group |
Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Group |
SSID | ssib053389439 ssj0000605265 ssib018287486 |
Score | 2.0965025 |
Snippet | BackgroundLapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival... Background Lapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival... |
SourceID | pubmedcentral proquest bmj |
SourceType | Open Access Repository Aggregation Database Publisher |
StartPage | A196 |
SubjectTerms | Brain cancer Breast cancer Cancer therapies Lymphatic system Metastasis Monoclonal antibodies Section 5: Patient safety and quality assurance Targeted cancer therapy |
SummonAdditionalLinks | – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwELUoLCwIBIhCQR5YDfFHEmdCgKgqJBBflbpFiWurrSANbWFm4Y_yS7hLnUIlxJDJUSKdz_Y7-_k9Qo45z5UBZAFFTiKZki5gqALFjLM6NsIErnKJuLmNOl113Qt7fsNt6mmV9ZxYTdT9scE98lOBUmF4nUGela8MXaPwdNVbaDTImuAKj2nXLq5u7x7qjOKVnPuPQBpgG9QbTxa7MEGEeifIcxQoWYDXPL0yKZfRqR0NShSQhlTimtlsUEKN6k4UOu028pfREipd5lT-WqTam2TDo0t6Pk-HLbJii23yFN493qPty9fHJzIu6nmCer9uOnb0OUNmdTHM6bCg0I2Czdlc75bmSFufUYPpMaFeh3W6Q7rtq6fLDvNmCiwXQSKYMEq5LMySPOaA-ZwOLUAFWN51qE0MK5SFkSqM5i62fWdkiEZTEoq_UCZZBEBtl6wW48LuEcotFGVaCQvFj9J9nnF4JO_L2HDtXNYkJxCctJzLZaRVmSGjtI5mitFM62imEM0madVxTP0QmuJbAdbPmv_dvMiHJomXQr_4MSpnL7cUw0GloB2jqE2s9___8AFZrzq-Ypy1yOps8mYPAYLM8iOfZ9_UedjL priority: 102 providerName: ProQuest |
Title | 5PSQ-068 Prescription profile of lapatinib in her2-positive breast cancer patients |
URI | http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.422 https://www.proquest.com/docview/2010338381 https://www.proquest.com/docview/2552768623 https://pubmed.ncbi.nlm.nih.gov/PMC7535278 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT4MwGG3cvHgxGjXOH0sPXmGUAi1HXbYsJi7zx5LdCHRthnFIdHr24j_qX-L3dTAl8eSBUyGQx1f6Hnl9HyEXjGWBAmYBIifmTsCN52AKlKOMlkL5yjO2S8TNOBpNg-tZONsiYb0Xxpr2VZa7xdPSLfKF9VaWS9WrfWK9yU1fYCaJkL0WaQnOmxKd2QT3n0w0oDMYMR5vfrx4EUacoLXRx5QC3NlZhZEyHvX046LEzGioHiYdnS5KkKXGDbC5bitbPjaIaNNG-WtdGu6R3YpQ0sv1g--TLV0ckIdwcn-LnV6-Pj7RZFF_GmjVops-G_qUopm6yDOaFxTenO-sDVzvmmboVF9RhRXxQqvo1ddDMh0OHvojp-qf4GS-F_uOr4LApGEaZ4IBzTMy1MAOYEWXoVQCFiUNk9NXkhmh50bxEHtLcdB7IY_TCLjZEWkXz4U-JpRp0GEy8DXonUDOWcrg4GzOhWLSmLRDXAAnKdcJGYlVFjxKajQTRDOp0UwAzQ45q3FMqlnzimd5KJkl-3sY0-JwRwvvENGAfnNjDMtujkAN2dDsqmZO_n3lKdmxNWH9Z2ekvXp50-dASFZZF8pwJrpk-2owntx1bTl-A9v_4TE |
link.rule.ids | 230,315,733,786,790,891,12083,21416,27955,27956,31752,33777,43343,43838,53825,53827,74100,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwELWgDLAgECDKpwdWQ2znw5kQIFCBtuKjlbpFiWurrSAttDCz8Ef5JdylTqESYsjkKJEu5_M75_k9Qo44z3wNyAKanFgyX1qPoQoU09aoSAvt2cIlotEMa23_phN03Ibb2NEqy5pYFOruUOMe-YlAqTA8ziBPRy8MXaPw76qz0FgkSyi5qSpk6fyyefdQZhQv5Nx_BNIA26DeeDzbhfFC1DtBnqNAyQI85umUSbkMT8ygN0IBaUglrphJeyPoUe2xj067i9nzYA6VznMqfy1SV2tk1aFLejZNh3WyYPIN0gruHu_R9uXr4xMZF2WdoM6vmw4tfUqRWZ33M9rPKXxGwaZsrndDM6StT6jG9HilTod1vEnaV5etixpzZgosE14smNC-b9MgjbOIA-azKjAAFWB5V4HSEaxQBmaq0IrbyHStlgEaTUlo_gIZpyEAtS1SyYe52SaUG2jKlC8MND--6vKUwyV5V0aaK2vTKjmG4CSjqVxGUrQZMkzKaCYYzaSMZgLRrJK9Mo6Jm0JjvMvD_lnxv4dn-VAl0VzoZy9G5ez5kbzfKxS0IxS1idTO_w8-JMu1VqOe1K-bt7tkpUiCgn22RyqT1zezD3Bkkh24nPsGO-zbwQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwELWgSIgFgQBRPj2wmsZ2EjsTQkBVPgUCpG5R4tpqK0gLLcws_FF-CXepU6iEGDI5SqTL2ffOeX6PkAPO89AAsoAmJ5EslC5gqALFjLNaGWECV7pEXN_Ercfwoh21Pf9p5GmV1ZpYLtSdgcE98oZAqTA8ziAbztMibk-bR8MXhg5S-KfV22nMkwWokgHaOKj2tLTyUtj9RyoNUA4qjyfT_ZggRuUTZDwKFC_AA59eo5TLuGH73SFKSUNScc1s1h1Ct-oOQ_Tcnc-f-zP4dJZd-atcNVfIsseZ9HiSGKtkzhZr5CG6vb9DA5ivj0_kXlQrBvXO3XTg6FOGHOuil9NeQeGDCjbhdb1bmiOBfUwNJsor9Yqso3Xy2Dx7OGkxb6vAchEkggkThi6LsiRXHNCf05EF0ACFXkfaKKhVFuasMJo7ZTvOyAgtpyS0gZFMshgg2wapFYPCbhLKLbRnOhQW2qBQd3jG4ZK8I5Xh2rmsTg4hOOlwIpyRlg2HjNMqmilGM62imUI062SnimPqJ9MI7wqwk9b87-FpZtSJmgn99MWooT07UvS6pZa2Qnkbpbf-f_A-WYRkS6_Oby63yVKZAyUNbYfUxq9vdhdwyTjfKxPuG5eD3n4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=5PSQ-068%E2%80%85Prescription+profile+of+lapatinib+in+her2-positive+breast+cancer+patients&rft.jtitle=European+journal+of+hospital+pharmacy.+Science+and+practice&rft.au=Paredes%2C+A+Madrid&rft.au=Herrera%2C+S+Guijarro&rft.au=Casanova%2C+N+Mart%C3%ADnez&rft.au=Garre%2C+M+Ca%C3%B1adas&rft.date=2018-03-01&rft.pub=BMJ+Group&rft.issn=2047-9956&rft.eissn=2047-9964&rft.volume=25&rft.issue=Suppl+1&rft.spage=A196&rft.epage=A196&rft_id=info:doi/10.1136%2Fejhpharm-2018-eahpconf.422&rft.externalDBID=PMC7535278 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9956&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9956&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9956&client=summon |